Official Symbol: BCL2L1provided by HGNC
Official Full Name: BCL2-like 1provided by HGNC
Primary Source: HGNC:992
See related: Ensembl:ENSG00000171552; HPRD:02497; MIM:600039
Gene type: protein coding
RefSeq status: REVIEWED
Organism: Homo sapiens
Lineage: Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; Homo
Also known as: BCLX; BCL2L; Bcl-X; bcl-xL; bcl-xS; BCL-XL/S; DKFZp781P2092; BCL2L1
Summary: The protein encoded by this gene belongs to the BCL-2 protein family. BCL-2 family members form hetero- or homodimers and act as anti- or pro-apoptotic regulators that are involved in a wide variety of cellular activities. The proteins encoded by this gene are located at the outer mitochondrial membrane, and have been shown to regulate outer mitochondrial membrane channel (VDAC) opening. VDAC regulates mitochondrial membrane potential, and thus controls the production of reactive oxygen species and release of cytochrome C by mitochondria, both of which are the potent inducers of cell apoptosis. Two alternatively spliced transcript variants, which encode distinct isoforms, have been reported. The longer isoform acts as an apoptotic inhibitor and the shorter form acts as an apoptotic activator. [provided by RefSeq]

[Top][Help]Genomic regions, transcripts, and products

(minus strand) Go to reference sequence details Try our new Sequence Viewer

[Top][Help]Genomic context

chromosome: 20; Location: 20q11.21See BCL2L1 in MapViewer

[Top][Help]Bibliography

GeneRIFs: Gene References Into Function What's a GeneRIF?

	1.	Studies create an important conclusion that PUMA promotes Bax translocation both by directly interacting with Bax and by competitive binding to Bcl-X(L) in UV-induced apoptosis.
	2.	Results suggest that an increased transcription of pro-apoptotic genes (p53 and Bcl-x(S)) in eutopic endometrium is significantly associated with endometriosis, which indicates dysregulation of apoptotic gene transcription associated with disease.
	3.	Na+/H+ exchanger mediates TNF-alpha-induced hepatocyte apoptosis via the calpain-dependent degradation of Bcl-xL.
	4.	hnRNP K has a role in preventing the production of the pro-apoptotic Bcl-x(S) splice isoform
	5.	Inhibition of host gene expression by the VSV M protein resulted in the degradation of Mcl-1 but not Bcl-X(L); inactivation of both Mcl-1 and Bcl-X(L) was required for cells to undergo apoptosis
	6.	Results demonstrated that the inhibition of spontaneous B cell apoptosis by CpG DNA was correlated to up-regulation of Bcl-xL, IAP and down-regulation of p53 and caspase 3 mediated through PI3K/AKT signaling.
	7.	Characterization of binding thermodynamics reveals that the interaction of BID with BCL-XL is driven by enthalpy but disfavored by the entropy associated with the conformational order induced in BID upon binding BCL-XL.
	8.	Data show that TGF-beta1 correlated with Bcl-xL and Bax in all colorectal cancers.
	9.	DAPk phosphorylates Beclin 1 on T119, a critical residue within its BH3 domain, and thus promotes Beclin 1 dissociation from Bcl-X(L) and autophagy induction.
	10.	Vacuolar H+-ATPase inhibitors overcome Bcl-X-mediated chemoresistance through restroration of a caspase-independent apoptotic pathway.
	11.	bcl-xL, through its antiapoptotic effect, might contribute to tumor cell survival in primary cutaneous follicule center lymphomas
	12.	Data show that DAPK phosphorylates beclin 1 on Thr 119 located at a crucial position within its BH3 domain, and thus promotes the dissociation of beclin 1 from Bcl-XL and the induction of autophagy.
	13.	Nucleotide excision repair may protect against cisplatin-induced apoptosis by activating NF-kappaB, which further induces transcription & accumulation of BCL-XL, and activation of the cell survival pathway.
	14.	up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia.
	15.	HIF-1alpha-dependent BCL-xL overexpression may be an important mechanism by which HIF-1alpha protects prostate cancer cells from apoptosis and leads to treatment resistance
	16.	expression of Bcl-XL protein was decreased by proteasome-mediated degradation prior to change of mRNA level in UVB-induced apoptotic basal cell carcinoma cell lines
	17.	two lesions differed significantly in expression of Bcl-xL which was present in 84% of the squamous cell carcinoma compared with only 15% in the keratoacanthoma
	18.	These results suggest that Bim, Bcl-xL, FAK and endonuclease G are involved in safingol-induced apoptosis of detached oral squamous cell carcinoma.
	19.	Beclin-1/Bcl-xl complexes in cells is decreased by increased expression of ARF, thereby providing a basis for ARF-induced autophagy
	20.	C/EBPbeta regulates bcl-xl gene expression in human breast cancer cells in response to cigarette smoke condensate treatment
	21.	Clinical trial of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
	22.	Bcl-xL phosphorylation induced by microtubule inhibitors plays a key pro-apoptotic role at least in part by disabling the ability of Bcl-xL to bind Bax.
	23.	Bcl-2 and bcl-xL have roles in cell death rates in transitional cell carcinoma cell lines
	24.	BCL2 and BCL-xL facilitation of G0 quiescence requires BAX, BAK, and p27 phosphorylation by Mirk
	25.	JAK2 promotes cell survival by signaling through the Pim/BAD/BCL-xL pathway
	26.	These observations suggest that Plk1 is a regulator of Bcl-x(L) phosphorylation and controls the anti-apoptotic activity of Bcl-x(L) during pironetin-induced apoptosis.
	27.	Results show that 072RB, a novel BH3-Bim-derived peptide inhibitor of Bcl-XL, inhibits leukemic cell growth.
	28.	Therefore, over-expression of Bcl-x(L) has a potential for amelioration of SMA, and Bcl-x(L) may be another attractive therapeutic target other than survival motor neuron (SMN) protein for use in future drug screening for SMA.
	29.	Results indicate that HBSP interacts with Bcl-2/Bcl-xl in vitro and induces apoptosis in HepG2 cells.
	30.	our results demonstrate the role of NF-kB as the mediator of bcl-xL-induced CXCL8 up-regulation in glioblastoma cells.
	31.	IL-3 up-regulates the expression of the antiapoptotic proteins cIAP2, Mcl-1, and Bcl-X(L) and induces a rapid and sustained de novo expression of the serine/threonine kinase Pim1 that closely correlates with cytokine-enhanced survival.
	32.	Bcl-x(L) and, to a lower extent, Mcl-1, are important anti-apoptotic factors in colorectal carcinoma.
	33.	Expressed in most dysmorphic neurons in focal cortical dysplasia type II.
	34.	VEGF, hTERT and Bcl-xl have roles in laryngeal squamous carcinoma
	35.	preoperative chemoradiotherapy (CRT) reduced Bcl-X(L) expression, and this decrease closely correlated with the prolonged survival of advanced esophageal cancer patients treated with preoperative CRT
	36.	Data show that the worm protein EGL-1 binds mammalian pro-survival proteins very poorly, but can be converted into a high-affinity ligand for Bcl-2 and Bcl-x(L) by mutation of the cysteine residue at position 62 within the BH3 domain.
	37.	the anti-apoptotic protein Bcl-xL is phosphorylated by benzylisothiocyanate treatment
	38.	Bcl-Xl deamidation and methylation has a role in protein isoaspartate methyltransferase prevention of apoptosis induced by oxidative stress in endothelial cells
	39.	Bcl-xL and UVRAG cause a monomer-dimer switch in Beclin1
	40.	the present study is the first report of a negative prognostic value for Bcl-XL in bilharzial squamous cell carcinoma of the urinary bladder
	41.	SRp30c stimulates splicing to the downstream 5' splice site of Bcl-x(L), thereby attenuating the repressive effect of upstream U1 snRNP binding sit
	42.	BCL-xL is itself responsible for the pre-senescence decline in the ability of a genotoxic stress to induce apoptosis
	43.	Bcl-xL protein levels were significantly higher in tissue samples from nonemphysematous smokers than in those from nonemphysematous nonsmokers
	44.	Bcl-xL plays an important role in carcinogenesis of human colorectal carcinoma and is associated with malignant biological behaviors of human colorectal carcinoma.
	45.	insulin-like growth factor 2 differentially regulated the intracellular translocation of Bcl-X(L)
	46.	Show that Bcl-XL was down-regulated and Bcl-XS was up-regulated in topotecan-induced apoptosis in HepG2 cells.
	47.	IGF1 promotes resistance to apoptosis in melanoma cells through an increased expression of BCL2, BCL-X(L), and survivin
	48.	BI-1 and Bcl-X(L) operate downstream of or parallel to Bax/Bak
	49.	while bcl-2 proteins are not required for ceramide to form protein-permeable channels in mitochondrial outer membranes, both recombinant human Bcl-x(L) and CED-9 disassemble ceramide channels in the mitochondrial outer membranes from rat liver and yeast
	50.	overexpression of Bcl-xL led to decreased cellular proliferation
	51.	Bcl-x was associated with increased survival in thymic neoplasms. Bcl-x:Bax ratio was also associated with survival.
	52.	androgen stimulates Bcl-xL expression via the androgen receptor and that increased Bcl-xL expression plays a versatile role in castration-resistant progression of prostate cancer
	53.	The Bcl-X(L) chimeras that are targeted to the mitochondria and the wild type Bcl-X(L) provided same protection against cell death under several death inducing conditions.
	54.	Observational study of gene-disease association. (HuGE Navigator)
	55.	Shp2E76K induces cytokine-independent survival of TF-1 cells by a novel mechanism involving up-regulation of Bcl-XL through the Erk1/2 pathway.
	56.	results indicate an action of Bcl-X(L) modulating human neural stem cell differentiation
	57.	activation of HSF1 and stabilization of Bcl-X(L) mediate a protective response that may contribute significantly to the cellular biology of lipid peroxidation
	58.	a caspase-9 signaling cascade induces feedback disruption of the mitochondrion through cleavage of anti-apoptotic Bcl-2, Bcl-xL, and Mcl-1
	59.	The protein kinase C (PKC) inhibitor and apoptotic inducer staurosporine switches the production of Bcl-x towards the x(S) mRNA isoform in 293 cells.
	60.	low dose doxorubicin-induced cell death through mitotic catastrophe may provide an alternative therapeutic strategy for Bcl-xL-overexpressing hepatoma cells
	61.	We conclude that alteration in the expression of proapoptotic (Bax, Bak) and antiapoptotic (Bcl-2, Bcl-XL) proteins on surface of thyroid follicular cells may play a role in the pathogenesis of thyroid autoimmune disorders.
	62.	Bcl-X(L) conferred complete resistance to apoptosis induced by fas ligation in atherosclerotic carotid artery.
	63.	The structure of Bcl-xL in complex with the Beclin-1 BH3 domain was determined at high resolution by NMR spectroscopy.
	64.	our results support the feasibility of using adenovirus-mediated RNA interference therapy targeting Bcl-XL against colon cancers and warrant further studies of its safety and efficacy.
	65.	Bcl-x(L) interacts with the DNA binding site of p53, but Bak does not interact with this site
	66.	xL is coupled to the stabilization of a cell-cycle checkpoint induced by DNA damage, and this effect is genetically distinct from its function on apoptosis
	67.	Data show that stimulation of PAR1 results in increased DNA binding of the NFkappaB p65 subunit, and that activation of PAR1 attenuates docetaxel induced apoptosis through the upregulation of Bcl-xL.
	68.	Bcl-x(L) plays an important role in human RPE cell survival under normal conditions and when cells are exposed to oxidative stress
	69.	preformed Bim(EL)/Mcl-1 and Bim(EL)/Bcl-x(L) complexes can be rapidly dissociated following activation of ERK1/2 by survival factors
	70.	Following UV treatment, Mcl-1 protein synthesis is blocked, the existing pool of Mcl-1 protein is rapidly degraded by the proteasome, and cytosolic Bcl-xL translocates to the mitochondria
	71.	CD28-stimulated T cells actively secrete IL-8, and Bcl-xL up-regulation protects T cells from radiation-induced apoptosis
	72.	Bcl-xL may have a role in underexpression of transcriptional regulators in metastatic breast cancer
	73.	overexpression of the Bcl-2 or Bcl-x(L) associated with the loss of apoptosis in breast cancer cells in vivo may account for their metastatic behavior
	74.	bcl-xL gene overexpression is linked to short overall survival times in follicular lymphoma.
	75.	Infection with OmpA+ E. coli induces the expression of Bcl(XL), an antiapoptotic protein, both at the mRNA level as assessed by gene array analysis and at the protein level
	76.	During endothelial cell apoptosis, Bcl-xl level showed no significant in HUVECs stimulated with TNF-alpha alone or in combination with IFN-gamma.
	77.	Data show that Bcl-x(L) expression is increased in the pulmonary artery undergoing chronic pulmonary vascular remodeling.
	78.	Bcl-XL siRNA contributes to an increase of cisplatin-induced cell death in non-small-cell lung cancer and sensitizes cells to cisplatin
	79.	retinoic acid-induced apoptotic signals were transduced via downregulation of Bcl-xL and the decrease in the mitochondrial membrane function leading to caspase-3 activation
	80.	gene expression level of beta-TUB, Bcl-XL, and GSTpi was closely correlated with the IC50 for docetaxel
	81.	role in inhibiting diamide-induced SM hydrolysis and ceramide accumulation but not the decrease in intracellular GSH
	82.	Bcl-x(L)-anti-apoptotic signal pathway seems to prevent mitochondrial multiple conductance channel opening, cytochrome c release and caspase-3 like activity following 6-OHDA treatment in the human neuroblastoma cell line SH-SY5Y
	83.	Jak-Stat and PI 3-kinase activation pathways regulate the TPO-induced survival of megakaryocytic cells via Bcl-xL gene expression.
	84.	Bcl-XL was higher in plaques than in normal white and gray matter in multiple sclerosis
	85.	Pim phosphorylation of Bad was also found to promote the 14-3-3 binding of Bad and block its association with Bcl-XL
	86.	Data suggest that Bcl-xl has a biochemical function that is capable of partially rescuing loss of function mutations in S. cerevisiae.
	87.	findings indicate that the levels of XIAP and Bcl-X(L) are regulated by distinct pathways during monocytic differentiation, and that upregulation of these proteins contributes to the increased longevity of cells in the monocytic lineage
	88.	the role of Bcl-x(L) in apoptosis in cardiomyocytes and discuss the potential use of Bcl-x(L) as a cardioprotective therapy for cardiac diseases.
	89.	role in sequestering proapoptotic Bak
	90.	A novel molecular mechanism of T-cell apoptosis that contributes to the SARS-CoV-induced lymphopenia observed in most SARS patients is reported.
	91.	p21-mediated cytoprotection against hyperoxia involves regulation of Bcl-XL and is uncoupled from its ability to inhibit proliferation
	92.	Bcl-XL is approximately ten times more active than Bcl-2 in repressing apoptosis induced by doxorubicin.
	93.	the conformation of the BAX alpha9-helix plays a significant role in BAX/BCL-xL interaction
	94.	Bcl-XL expression is induced by HIV-1 Nef in macrophages in an extracellular signal-regulated kinase-dependent manner
	95.	bcl-xl-mediated changes in metabolic pathways of breast cancer cells were studied from survival in the blood stream to organ-specific metastasis.
	96.	Bcl-xL is deamidated in the cellular response to DNA damage and leads to apoptosis resistance
	97.	Bcl-x(L) is a key target mediating the anti-apoptotic effects of glucocorticoids during fibrosarcoma development
	98.	selective expression of Bcl-xL may be involved in the difference in the susceptibility to cell death between immature dendritic cells and mature dendritic cells .
	99.	Rapamycin induces apoptosis of tumor cells by increasing the ratio of Bax to Bcl-xL through mechanisms dependent and independent of its mTOR inhibitory activity
	100.	these data suggest the solution to membrane conformational change is controlled by an electrostatic mechanism
	101.	data demonstrate that OX40 and Bcl-x(L) can control survival of primed CD8 T cells and provide new insights into both regulation of CD8 immunity and control of tumors
	102.	catalase has a critical role in CSF-independent survival of human macrophages via regulation of the expression of BCL-2 and BCL-XL
	103.	Significant coexpression of GLUT-1, Bcl-xL, and Bax points to cooperation of all three regulatory proteins in elimination due to irreversible injury, adaptation to hypoxia, reduction of further damage, and survival of colorectal cancer cells.
	104.	Bcl-XL protects BimEL-induced Bax conformational change and cytochrome C release.
	105.	Natural cytotoxic T cell-defined reactivity is detected against Bcl-xL in peripheral blood leukocytes from patients with breat cancer and melanoma.
	106.	Bcl-2 may not play a physiological role in antagonizing apoptosis signals pertinent to BAD activation in prostate cancer cells
	107.	Overexpression of bcl-2 and bcl-xL leading to prolonged survival of mast cells may contribute to the pathogenesis of mastocytosis.
	108.	Bcl-xL in hepatocellular carcinoma specimens. Bcl-xL may be significant prognostic factor for disease progression in human hepatocellular carcinoma.
	109.	T cell blasts surviving activation-induced cell deathare memory CD44 high cells with increased Bcl-xL expression.
	110.	hnRNP F/H proteins have a positive role in the production of the proapoptotic regulator Bcl-x(S)
	111.	In addition, B cell lymphoma leukemia (Bcl)-x(L), an antiapoptotic regulator, was also highly expressed in macrophages from smokers compared with nonsmokers and subjects with asthma.
	112.	Overexpressed Bcl-xL reduced time-dependent increase of apoptosis induced by ionizing radiation.ROS generation and Bax expression were also lower.These results provide insights into a new strategy for gene therapy of radiation-induced immune injury.
	113.	Bcl-xL prevents TRAIL-induced apoptosis by abrogating caspase activation and cleavage of BH3 interacting domain death agonist protein in acute myelogenous leukemia HL-60 cells.
	114.	Overexpression of bcl-xl is associated with colonic neoplasms
	115.	c-erb-B2 and Bcl-xl expression can be useful for the histopatologic diagnosis of Barrett exophagux and correct interpretation of dysplasia.
	116.	There may be a dominance expression of proapoptotic proteins in optic nerve axons in glaucoma.
	117.	Bcl-X(L) may regulate Bax translocation through modulation of protein phosphatase or kinase signaling.
	118.	treatment with an antisense oligonucleotide (5'Bcl-x AS) shifts the splicing pattern of Bcl-x pre-mRNA from the anti-apoptotic variant, Bcl-xL, to the pro-apoptotic variant, Bcl-xS
	119.	a novel role in cell fate decisions /during hematopoietic differentiation/ beyond cell survival
	120.	Bcl-XL has a role in suppressing proliferation of 5-fluorouracil-resistant human colon cancer cells
	121.	Bcl-xl has a role in suppressing a p53 and Bax-dependent apoptotic pathway in colorectal cancer cells
	122.	Human Bcl-xL is deamidated at asparagines 52 and 66 & the rate of deamidation is significantly lower in hepatocellular carcinomas than in normal liver. Tumor cells may gain apoptosis resistance & a survival advantage by suppressing Bcl-xL deamidation.
	123.	Mature dendritic cells are protected from Fas/CD95-mediated apoptosis by upregulation of Bcl-X(L).
	124.	Reduced levels of Bcl-xL may play an important role in the increased sensitivity to apoptosis of HIV-specific CD8+ T cells.
	125.	HER-2 overexpression is highly correlated with the expression of the apoptosis-suppressing gene bck-xL.
	126.	Role of bcl-xl protein on indomethacin-induced cell division inhibition in chronic myelogenous leukemia cells.
	127.	Significant correlation between Bcl-x(L) expression and number of inflammatory cells in subsynovium of rheumatoid arthritis and osteoarthritis patients. May play role in extended survival of synoviocytes and inflammatory cells in rheumatoid synovium.
	128.	the interaction of BAD with membranes is tied to binding of 14-3-3 protein and activation and membrane translocation of Bcl-XL
	129.	Downregulation of Bcl-xL (but not Bcl-2, Bax, or Bid) connects cathepsin D and the mitochondrial pathway during glucosamine sulfate-induced apoptosis.
	130.	Bcl-xL can bind to one or two VDAC1 molecules forming heterodimers and heterotrimers.
	131.	Bcl-xl over-expression does not confer protection against cell death in U937 cells.
	132.	Overexpression of antiapoptotic proteins Bcl-2 and Bcl-X(L) and down-regulation of caspase-3 activity may be associated with cisplatin resistance in human ovarian cancer.
	133.	ligand engagement of uPAR promotes cell survival by activating Bcl-xL transcription through the MEK/ERK- and phosphatidylinositol 3-kinase/Akt-dependent pathways
	134.	dissociation of Bad from Bcl-xL and an increase in the intracellular level of Bcl-xL are responsible for development of acquired TRAIL resistance
	135.	Antiapoptotic proteins Bcl-2 and Bcl-X(L) bind and suppress NALP1, reducing caspase-1 activation and interleukin-1beta (IL-1beta) production.
	136.	We speculate that the TM1 helices of Bax may serve as 'structural antagonists' for BH3-Bcl-xL interactions.
	137.	Bcl-xL inhibits p53- but not apoptin-induced apoptosis in head and neck neoplasms
	138.	androgen receptor silencing has a role in apoptotic cell death by disrupting the Bcl-xL-mediated survival signal in human prostate cancer cell lines
	139.	regulation of alternative splicing in lung adenocarcinoma cells by de novo ceramide
	140.	Therefore, Bcl-X(L), a promising therapeutic candidate for ischemia and neurodegenerative diseases, is only of partial efficacy in preventing the direct neurotoxicity of pneumolysin.
	141.	Expression of Cx26, Bax and Bcl-xL in colorectal cancers. Association of Cx26, Bax and Bcl-xLwith histological G2 grade of tumors.
	142.	Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells.
	143.	Bcl-XL has a role in preventing Bax activation at the mitochondrial membrane
	144.	The amphipathic alpha 6 helix fragment of Bcl-xL inserts in membranes as part of the alpha 5-alpha 6 hairpins in a model chimeric system, showing direct potentiality for this Bcl-xL fragment to acquire a membrane inserted state.
	145.	BCL-XL is induced during rapamycin-resistant proliferation of CD8+ T cells
	146.	The BCLX pre-mRNA is splicing by extracellular factors and their distinct requirements for pre-mRNA elements.
	147.	Stable Bcl-XL siRNA transfectants have an increased spontaneous apoptosis.
	148.	Data show that Bcl-x(L) in the cytosol forms homodimers, and that the C-terminal hydrophobic tails of two Bcl-x(L) molecules are involved in homodimer formation.
	149.	Bcl-xL/Bax ratio can block the apoptotic response in TNFalpha-stimulated cells but allows cell death initiation when it is altered by a crosstalk between IFNgamma presensitization and TNFalpha induced signaling.
	150.	PXR expression is required for Bcl-2 and Bcl-xL up-regulation upon PXR activators treatment in human and rat hepatocytes.
	151.	Results describe the structure of BCL-X(L) homodimers as a 3D-domain swapped dimer.
	152.	PUMA initiates apoptosis in part by dissociating Bax and Bcl-X(L), thereby promoting Bax multimerization and mitochondrial translocation
	153.	Bcl-xL is capable of giving rise to Epo-independent erythroid colony formation.
	154.	Radiation therapy for squamous cell carcinoma of cervix results in increased apoptosis with the up-regulation of Bax, a proapoptotic protein, the down-regulation of Bcl-XL, an antiapoptotic protein, and no significant change in the levels of Bcl-2.
	155.	Expression of Bcl-x was strongly expression in both reactive astrocytes and astrocytomas. Expression of Bcl-x is more focal in oligodendrogliomas, with staining of mainly intervening astrocytic processes.
	156.	distal Bcl-X 1B promoter plays a critical role in driving constitutive expression-mediated via Ets family proteins in malignant B cells
	157.	GX15-070 induced apoptosis in vitro in MCL cell lines and primary cells from patients with MCL by releasing Bak from Mcl-1 and Bcl-X(L).
	158.	In Parkinson's disease patients, Bcl-xL mRNA expression per dopaminergic neuron is almost double that of controls, an effect that may be mediated by a redistribution of Bcl-xL from the cytosol to the outer mitochondrial membrane.
	159.	role in modulating HIV-1/monocyte-derived macrophage-induced neuronal apoptosis
	160.	A very low mRNA level was indicated at bax, bcl-2 and bcl-xL in hepatocellular carcinoma tissues in contrast to normal liver.
	161.	Anti-apoptotic factors, Bcl-2 and Bcl-xL, were significantly decreased in epithelial cells under a hypoxic condition as assessed by Western blotting
	162.	1-Bromopropane inhibits nuclear factor kappa B activation to reduce Bcl-xL expression in astrocytes.
	163.	Thus EPO promotes survival of endothelial cells through PI3K-dependent Bcl-x(L)-induction and BIM regulation, as well as through a separate mechanism involving the ERK pathway.
	164.	increased expression associated with low levels of apoptosis in renal cell carcinoma; may have role in progression of cancer and treatment resistance
	165.	Erythrocyte survival is suppressed by a Bak-derived BH3 peptide that interacts with membrane-associated Bcl-X(L).
	166.	bcl-xL directly binds to Apaf-1.
	167.	show that the Bcl-x(L) interaction surface on p53 involves the same region that is used by the protein to contact DNA. The p53-binding site on Bcl-x(L) is also defined.
	168.	p38 MAPK and Bcl-XL expression play critical roles in the survival of UVA-irradiated HaCaT cells
	169.	The role of Bcl-xL in megakaryocyte (MK) differentiation was studied using siRNA to block its expression in essential thrombocythemia, chronic myeloid leukemia, & polycythemia vera cells. It is down-regulated early in MK differentiation of MKs from ET.
	170.	Mitochondrial targeting of Bcl-x(L) requires the COOH-terminal transmembrane (TM) domain flanked at both ends by at least two basic amino acids
	171.	Fibroblast growth factor-2 induces translational regulation of Bcl-XL and Bcl-2 via a MEK-dependent pathway: correlation with resistance to etoposide-induced apoptosis
	172.	results show a pivotal role for Bcl-XL in ALK-mediated oncogenicity
	173.	Transgenic mice crrossed with c-MYC transgenic mice develop multiple myeloma.
	174.	The results of the current study suggest that the potential ability of 15d-PGJ(2) in regulation of cell cycle and inhibition of Bcl-xL expression might be beneficial in the development of novel pharmacological agents for chondrosarcoma.
	175.	ABL-MYC retroviral infection only elicits bone marrow plasma cell tumors in mice that ectopically express Bcl-X(L) in their B- and plasma cells.
	176.	BCL-xL levels decreased when H202 was greater than 250 micro M.
	177.	Gossypol is a potent and novel therapeutic able to overcome apoptosis resistance by specifically targeting the activity of antiapoptotic Bcl-2 and Bcl-xl family members.
	178.	Gossypol induced complete cytochrome c release from mitochondria, increased caspases-3 and -9 activity, and caused apoptotic death without affecting protein levels of Bcl-2 and Bcl-X(L.)
	179.	Bcl-xL expression contributes to androgen resistance and progression of prostate cancer
	180.	These results suggest a relevant role for STAT5 and Bcl-xL as apoptosis-regulatory proteins in the pathogenesis of lung cancer, and overexpression of both Neu and activated STAT3, could be related with the proliferation rate in lung carcinoma cells.
	181.	overexpression of Bcl-x(L) or Bcl-2 in PC12 cells markedly suppressed brefeldin A-induced activation of caspases and resulting cell death.
	182.	recombinant GM-CSF-Bcl-XL binds the GM-CSF receptor on human monocyte/macrophage cells and bone marrow progenitors inducing differentiation and allowing Bcl-XL entry into cells
	183.	severe acute respiratory syndrome coronavirus 7a protein induction of apoptosis is dependent on its interaction with the Bcl-XL protein
	184.	Bcl-xl RNA silencing in transfected HepG2 cells induced apoptosis and increased sensitivity of cells to 5-FU and 10-hydroxycamptothecin.
	185.	Bcl-xL and E1B-19K proteins inhibit p53-induced irreversible growth arrest and senescence by preventing reactive oxygen species-dependent p38 activation
	186.	BCL-XL binds to Siva-1 putative amphipathic helical region which sensitizes cells to UV radiation induced apoptosis
	187.	identified SAP155 as an RNA trans-acting factor that binds to CRCE 1, functions to regulate the alternative 5' splice site selection of Bcl-x pre-mRNA, and is required for ceramide to induce the activation of the Bcl-x(s) 5' splice site
	188.	Results describe the specific modulation of apoptosis and Bcl-xL phosphorylation in yeast by distinct mammalian protein kinase C isoforms.
	189.	This study is the first to show a clear dissociation between changes in Bcl-2 expression (downregulation) and Bcl-XL, Mcl-1 expression (upregulation) during progression of melanoma.

Submit: New GeneRIF Correction

[Top][Help]HIV-1 protein interactions

Protein	Interaction
1. Envelope surface glycoprotein gp160, precursor	Treatment of CD4+ cells with HIV-1 gp160 causes intracellular calcium increase followed by the release of cytochrome c from mitochondria; association of BAD with Bcl-xL is observed, and a portion of BAD is dephosphorylated after gp160 induction	PubMed
2. Nef	HIV-1 Nef enhances apoptosis in CD4+ human lymphoblastoid cell lines through mechanisms that include the downregulation of the anti-apoptotic proteins Bcl-2 and Bcl-XL	PubMed
3.	HIV-1 Nef suppresses apoptosis of TF-1 macrophages by upregulating mitochondrial anti-apoptosis protein Bcl-XL expression; cell survival and Bcl-XL induction by Nef are dependent on the Erk/MAPK pathway, but independent of PI3K and Akt activation	PubMed
4. Tat	HIV-1 Tat upregulates several anti-apoptotic genes, including AKT-1, AKT-2, BCL2, BCL-XL, and insulin-like growth factor I in vincristine-treated Kaposi's sarcoma cells	PubMed
5. Vpr	Expression of HIV-1 Vpr causes redistribution of Bcl-X protein into an organized, network-like manner to form filamentous structures	PubMed
6.	HIV-1 Vpr downregulated Bcl-X expression in transgenic mice suggesting a role in Vpr mediated apoptosis of T lymphocytes	PubMed
7. Vpu	Levels of Bcl-xL are reduced in T cells as a result of HIV-1 Vpu-mediated inhibition of NF-kappa B activation	PubMed

Go to the HIV-1, Human Protein Interaction Database

[Top][Help]Interactions

Description ..........
Product	Interactant	Other Gene	Complex	Source	Pubs

BCLX	NP_001008709.1	PPP1CA		HPRD	PubMed
HalphaA-crystallin interacts with Bcl-Xs.
NP_001182.1	NP_000385.1	CRYAA		BIND	PubMed
HalphaB-crystallin interacts with Bcl-Xs.
NP_001182.1	NP_001876.1	CRYAB		BIND	PubMed

NP_612815.1	Tumor endothelial marker 8	ANTXR1		HPRD	PubMed

NP_612815.1	APAF1	APAF1		HPRD	PubMed

NP_612815.1	Apoptotic protease activating factor	APAF1		HPRD	PubMed

NP_612815.1	Cell death regulator Aven	AVEN		HPRD	PubMed

NP_612815.1	BCL2 antagonist of cell death	BAD		HPRD	PubMed

NP_612815.1	NP_004313.1	BAD		HPRD	PubMed

NP_612815.1	NP_004313.1	BAD		HPRD	PubMed
Bad interacts with Bcl-XL.
NP_612815.1	NP_004313.1	BAD		BIND	PubMed
Bad interacts with Bcl-xL.
NP_612815.1	NP_004313.1	BAD		BIND	PubMed
Bcl-XL interacts with Bad. This interaction was modelled on a demonstrated interaction between Bcl-XL from an unspecified species and human Bad.
NP_612815.1		BAD		BIND	PubMed

NP_612815.1	BAG 1	BAG1		HPRD	PubMed

NP_612815.1	NP_001179.1	BAK1		HPRD	PubMed
Bax interacts with Bcl-XL via its BH3 domain. This interaction was modeled on a demonstrated interaction between mouse Bax and human Bcl-XL.
NP_612815.1	NP_620116.1	BAX		BIND	PubMed
Bax interacts with Bcl-xL.
NP_612815.1	NP_620116.1	BAX		BIND	PubMed
Bax interacts with Bcl-XL.
NP_612815.1		BAX		BIND	PubMed
Puma interacts with Bcl-XL.
NP_612815.1	NP_055232.1	BBC3		BIND	PubMed
PUMA interacts with Bcl-xL.
NP_612815.1	NP_055232.1	BBC3		BIND	PubMed
Bcl-XL interacts with Puma. This interaction was modelled on a demonstrated interaction between Bcl-XL from an unspecified species and human Puma.
NP_612815.1	NP_055232.1	BBC3		BIND	PubMed

NP_612815.1	NP_005736.3	BCAP31		HPRD	PubMed

NP_612815.1	Bcl 2	BCL2		HPRD	PubMed

NP_612815.1	NP_065129.1	BCL2L10		HPRD	PubMed

NP_612815.1	BCL2 interacting protein BIM	BCL2L11		HPRD	PubMed

NP_612815.1	BCL2 interacting protein BIM	BCL2L11		HPRD	PubMed
Bim interacts with Bcl-XL.
NP_612815.1	NP_006529.1	BCL2L11		BIND	PubMed
Bcl-XL interacts with Bim. This interaction was modelled on a demonstrated interaction between Bcl-XL from an unspecified species and human Bim.
NP_612815.1		BCL2L11		BIND	PubMed

NP_612815.1	Apoptosis regulator BCLG	BCL2L14		HPRD	PubMed

NP_612815.1	NP_055554.1	BCLAF1		HPRD	PubMed

NP_612815.1	NP_003757.1	BECN1		HPRD	PubMed
BCL-XL interacts with the alpha-helical region of the BID BH3 death domain.
NP_612815.1	NP_001187.1	BID		BIND	PubMed
Bid interacts with Bcl-XL.
NP_612815.1	NP_001187.1	BID		BIND	PubMed
Bid interacts with Bcl-xL.
NP_612815.1	NP_001187.1	BID		BIND	PubMed
BCL-XL interacts with the alpha-helical region of the BID-EL BH3 death domain.
NP_612815.1	NP_932070.1	BID		BIND	PubMed
Bcl-XL interacts with Bid. This interaction was modelled on a demonstrated interaction between Bcl-XL from an unspecified species and human Bid.
NP_612815.1		BID		BIND	PubMed

NP_612815.1	NP_001188.1	BIK		HPRD	PubMed

NP_612815.1	NP_001188.1	BIK		HPRD	PubMed
Bik interacts with Bcl-XL.
NP_612815.1	NP_001188.1	BIK		BIND	PubMed
Bcl-XL interacts with Bik. This interaction was modelled on a demonstrated interaction between Bcl-XL from an unspecified species and human Bik.
NP_612815.1	NP_001188.1	BIK		BIND	PubMed
Bmf interacts with Bcl-XL. This interaction was modelled on a demonstrated interaction between mouse Bmf and human Bcl-XL.
NP_612815.1	NP_001003940.1	BMF		BIND	PubMed
Bcl-XL interacts with Bmf. This interaction was modelled on a demonstrated interaction between Bcl-XL from an unspecified species and human Bmf.
NP_612815.1	NP_001003940.1	BMF		BIND	PubMed

NP_612815.1	NP_053583.1	BNIP1		HPRD	PubMed

NP_612815.1	NP_053583.1	BNIP1		HPRD	PubMed

NP_612815.1	Bcl2/adenovirus E1B 19 kD protein interacting protein 3	BNIP3		HPRD	PubMed

NP_612815.1	NP_004322.1	BNIP3L		HPRD	PubMed

NP_612815.1	NP_004322.1	BNIP3L		HPRD	PubMed

NP_612815.1	Caspase 8	CASP8		HPRD	PubMed

NP_612815.1	Caspase 9	CASP9		HPRD	PubMed

NP_612815.1	c-FLIP	CFLAR		HPRD	PubMed

NP_612815.1	Cytochrome C	CYCS		HPRD	PubMed

NP_612815.1	NP_036313.2	FKBP8		HPRD	PubMed

NP_612815.1	BCL2 interacting protein	HRK		HPRD	PubMed

NP_612815.1	NP_003797.1	HRK		HPRD	PubMed

NP_612815.1	NP_003797.1	HRK		HPRD	PubMed
Hrk interacts with Bcl-XL.
NP_612815.1	NP_003797.1	HRK		BIND	PubMed
Bcl-XL interacts with Hrk. This interaction was modelled on a demonstrated interaction between Bcl-XL from an unspecified species and human Hrk.
NP_612815.1	NP_003797.1	HRK		BIND	PubMed
Hrk interacts with Bcl-XL.
NP_612815.1	NP_003797.1	HRK		BIND	PubMed

NP_612815.1	Zinc finger protein, subfamily 1A, member 3	IKZF3		HPRD	PubMed

NP_612815.1	IRS 1	IRS1		HPRD	PubMed

NP_612815.1	IRS2	IRS2		HPRD	PubMed

NP_612815.1	NP_071434.2	MOAP1		HPRD	PubMed
MAP-1 interacts with Bcl-XL via its amino and carboxy terminal regions.
NP_612815.1	NP_071434.2	MOAP1		BIND	PubMed

NP_612815.1	NP_066950.1	PMAIP1		HPRD	PubMed

NP_612815.1	NP_000012.1	PSEN1		HPRD	PubMed

NP_612815.1	Presenilin 2	PSEN2		HPRD	PubMed

NP_612815.1	NP_066959.1	RTN1		HPRD	PubMed
NSP-C interacts with Bcl-XL.
NP_612815.1	NP_996734.1	RTN1		BIND	PubMed

NP_612815.1	NP_065393.1	RTN4		HPRD	PubMed
RTN-XS interacts with Bcl-XL.
NP_612815.1	NP_722550.1	RTN4		BIND	PubMed

NP_612815.1	NP_006418.2	SIVA1		HPRD	PubMed

NP_612815.1	Synuclein alpha	SNCA		HPRD	PubMed

NP_612815.1	NP_114427.1	SPNS1		HPRD	PubMed

NP_612815.1	Bax inhibitor 1	TMBIM6		HPRD	PubMed

NP_612815.1	NP_000537.2	TP53		HPRD	PubMed
Bcl-xl interacts with p53.
NP_612815.1	NP_000537.2	TP53		BIND	PubMed
Bcl-xL interacts with TCTP.
NP_612815.1	NP_003286.1	TPT1		BIND	PubMed

NP_612815.1	NP_003365.1	VDAC1		HPRD	PubMed

NP_612815.1	PP1 alpha			HPRD	PubMed

NP_612815.1	RTN-Xs			HPRD	PubMed
Affinity Capture-Western
BioGRID:107070	BioGRID:106814	APAF1		BioGRID	PubMed
Affinity Capture-Western; Two-hybrid
BioGRID:107070	BioGRID:121366	AVEN		BioGRID	PubMed
Affinity Capture-Western; Protein-peptide; Reconstituted Complex; Two-hybrid
BioGRID:107070	BioGRID:107048	BAD		BioGRID	PubMed
Affinity Capture-Western; FRET; Protein-peptide; Reconstituted Complex; Two-hybrid
BioGRID:107070	BioGRID:107054	BAK1		BioGRID	PubMed
Affinity Capture-Western; Protein-peptide
BioGRID:107070	BioGRID:107057	BAX		BioGRID	PubMed
Affinity Capture-Western
BioGRID:107070	BioGRID:118009	BBC3		BioGRID	PubMed
Affinity Capture-Western; Reconstituted Complex
BioGRID:107070	BioGRID:115437	BCAP31		BioGRID	PubMed
Affinity Capture-Western; Protein-peptide
BioGRID:107070	BioGRID:107068	BCL2		BioGRID	PubMed
Affinity Capture-Western; FRET; Two-hybrid
BioGRID:107070	BioGRID:115335	BCL2L11		BioGRID	PubMed
Affinity Capture-Western
BioGRID:107070	BioGRID:122658	BCL2L14		BioGRID	PubMed
Two-hybrid
BioGRID:107070	BioGRID:114226	BECN1		BioGRID	PubMed
Protein-peptide
BioGRID:107070	BioGRID:107106	BID		BioGRID	PubMed
Affinity Capture-Western; Protein-peptide; Two-hybrid
BioGRID:107070	BioGRID:107107	BIK		BioGRID	PubMed
Reconstituted Complex
BioGRID:107070	BioGRID:107109	BLK		BioGRID	PubMed
Reconstituted Complex
BioGRID:107070	BioGRID:107130	BNIP1		BioGRID	PubMed
Affinity Capture-Western; Two-hybrid
BioGRID:107070	BioGRID:107132	BNIP3		BioGRID	PubMed
Reconstituted Complex; Two-hybrid
BioGRID:107070	BioGRID:127211	BNIPL		BioGRID	PubMed
Affinity Capture-Western; Protein-peptide; Two-hybrid
BioGRID:107070	BioGRID:198352	Bcl2l11		BioGRID	PubMed
Phenotypic Suppression
BioGRID:107070	BioGRID:107285	CASP2		BioGRID	PubMed
Phenotypic Suppression
BioGRID:107070	BioGRID:107291	CASP8		BioGRID	PubMed
Affinity Capture-Western
BioGRID:107070	BioGRID:107292	CASP9		BioGRID	PubMed
MRIT-alpha-1 interacts with BclXL. This interaction was modelled on a demonstrated interaction between human MRIT-alpha-1 and BclXL from an unspecified species.
	NP_003870.3	CFLAR		BIND	PubMed
Affinity Capture-Western
BioGRID:107070	BioGRID:114364	CFLAR		BioGRID	PubMed
Affinity Capture-Western
BioGRID:107070	BioGRID:119922	CYCS		BioGRID	PubMed
Affinity Capture-Western
BioGRID:107070	BioGRID:114206	DYNLL1		BioGRID	PubMed
Affinity Capture-Western
BioGRID:107070	BioGRID:117270	FKBP8		BioGRID	PubMed
Affinity Capture-Western; FRET; Two-hybrid
BioGRID:107070	BioGRID:114276	HRK		BioGRID	PubMed
Affinity Capture-Western; Two-hybrid
BioGRID:107070	BioGRID:116484	IKZF3		BioGRID	PubMed
Affinity Capture-Western
BioGRID:107070	BioGRID:109874	IRS1		BioGRID	PubMed
Affinity Capture-Western
BioGRID:107070	BioGRID:110338	MCL1		BioGRID	PubMed
Affinity Capture-Western
BioGRID:107070	BioGRID:122069	MOAP1		BioGRID	PubMed
Affinity Capture-Western; Protein-peptide
BioGRID:107070	BioGRID:111379	PMAIP1		BioGRID	PubMed
Affinity Capture-Western; Reconstituted Complex
BioGRID:107070	BioGRID:111493	PPP1CA		BioGRID	PubMed
Two-hybrid
BioGRID:107070	BioGRID:111642	PSEN1		BioGRID	PubMed
Affinity Capture-Western; Two-hybrid
BioGRID:107070	BioGRID:111643	PSEN2		BioGRID	PubMed
Affinity Capture-Western; Two-hybrid
BioGRID:107070	BioGRID:111820	RAD9A		BioGRID	PubMed
Reconstituted Complex
BioGRID:107070	BioGRID:111831	RAF1		BioGRID	PubMed
Affinity Capture-Western; Two-hybrid
BioGRID:107070	BioGRID:112165	RTN1		BioGRID	PubMed
Affinity Capture-Western; Two-hybrid
BioGRID:107070	BioGRID:121400	RTN4		BioGRID	PubMed
Affinity Capture-Western
BioGRID:107070	BioGRID:123836	SPNS1		BioGRID	PubMed
Affinity Capture-Western; Reconstituted Complex
BioGRID:107070	BioGRID:113259	VDAC1		BioGRID	PubMed

[Top][Help]General gene information

Markers

BCL2L1(e-PCR): Links: UniSTS:505873

PMC156147P6(e-PCR): Links: UniSTS:271383

PMC84055P1(e-PCR): Links: UniSTS:273437

PMC84055P2(e-PCR): Links: UniSTS:273438

BCL2L1_1568(e-PCR): Links: UniSTS:277026

PMC20354P5(e-PCR): Links: UniSTS:271938

PMC300830P1(e-PCR): Links: UniSTS:272474

PMC316415P1(e-PCR): Links: UniSTS:272987

Bcl2l(e-PCR), detects polymorphism: Links: UniSTS:141168

RH25072(e-PCR): Links: UniSTS:90736

D17S2108(e-PCR): Links: UniSTS:4510

PMC196230P1(e-PCR): Links: UniSTS:271802

PMC262691P2(e-PCR): Links: UniSTS:272324

PMC92563P1(e-PCR): Links: UniSTS:273619

PMC92563P2(e-PCR): Links: UniSTS:273620

PMC92563P3(e-PCR): Links: UniSTS:273621

Z94537(e-PCR): Links: UniSTS:14580

Genotypes

See BCL2L1 SNP Genotype Report

See BCL2L1 SNP Geneview Report

Homology

Homologs of the BCL2L1 gene The BCL2L1 gene is conserved in chimpanzee, dog, cow, mouse, rat, chicken, and zebrafish.

Map Viewer (Mouse, Rat)

Pathways

KEGG pathway: Amyotrophic lateral sclerosis (ALS): 05014
KEGG pathway: Apoptosis: 04210
KEGG pathway: Chronic myeloid leukemia: 05220
KEGG pathway: Jak-STAT signaling pathway: 04630
KEGG pathway: Pancreatic cancer: 05212
KEGG pathway: Pathways in cancer: 05200
KEGG pathway: Small cell lung cancer: 05222
Reactome Event:Apoptosis: REACT_578

Gene Ontology Provided by GOA

Function	Evidence
caspase inhibitor activity	IEA
identical protein binding	IPI	PubMed
protein heterodimerization activity	IEA

Process	Evidence
fertilization	IEA
germ cell development	IEA
growth	IEA
in utero embryonic development	IEA
male gonad development	IEA
negative regulation of neuron apoptosis	IEA
negative regulation of survival gene product expression	TAS	PubMed
ovarian follicle development	IEA
positive regulation of anti-apoptosis	IEA
positive regulation of apoptosis	IEA
positive regulation of cell proliferation	IEA
regulation of mitochondrial membrane permeability	IDA	PubMed
regulation of mitochondrial membrane potential	IDA	PubMed
release of cytochrome c from mitochondria	IDA	PubMed
response to cycloheximide	IEA
response to cytokine stimulus	IDA	PubMed
response to hydrogen peroxide	IEA
response to hypoxia	IEA
response to inorganic substance	IEA
response to lead ion	IEA
response to organic cyclic substance	IEA
response to organic nitrogen	IEA
response to oxidative stress	IEA
response to peptide hormone stimulus	IEA
response to protein stimulus	IEA
response to radiation	IEA
spermatogenesis	IEA

Component	Evidence
cytosol	IEA
integral to membrane	IEA
intracellular	IEA
membrane	IEA
mitochondrial outer membrane	EXP	PubMed
mitochondrial outer membrane	NAS	PubMed
mitochondrion	IDA	PubMed
nucleus	IEA

[Top][Help]General protein information

Preferred Names: BCL2-like 1

Names: BCL2-like 1; OTTHUMP00000030550

[Top][Help]NCBI Reference Sequences (RefSeq)

RefSeqs maintained independently of Annotated Genomes

These reference sequences exist independently of genome builds. Explain

mRNA and Protein(s)

NM_001191.2 → NP_001182.1 BCL2-like 1 isoform 2

Description

Transcript Variant: This variant (2) is also known as bcl-xS or bcl-x beta. It lacks an exon within the coding region when compared to variant 1. The translation remains in-frame, and results in a shorter isoform (2) that lacks an internal segment, as compared to isoform 1.

Source sequence(s)

Z23116

Consensus CDS

CCDS13188.1

UniProtKB/Swiss-Prot

Q07817

UniProtKB/TrEMBL

Q5TE63

Conserved Domains (3) summary

TIGR00865
Location:126 – 170
Blast Score: 135

bcl-2; Apoptosis regulator

cl02540
Location:1 – 27
Blast Score: 121

BH4; Bcl-2 homology region 4

cl02575
Location:81 – 125
Blast Score: 133

Bcl-2_like; Apoptosis regulator proteins of the Bcl-2 family, named after B-cell lymphoma 2. This alignment model spans what have been described as Bcl-2 homology regions BH1, BH2, BH3, and BH4. Many members of this family have an additional C-terminal...
NM_138578.1 → NP_612815.1 BCL2-like 1 isoform 1

Description

Transcript Variant: This variant (1) is also known as bcl-xL. It encodes a longer isoform (1).

Source sequence(s)

BC019307

Consensus CDS

CCDS13189.1

UniProtKB/Swiss-Prot

Q07817

Conserved Domains (3) summary

TIGR00865
Location:1 – 233
Blast Score: 833

bcl-2; Apoptosis regulator

cd06845
Location:81 – 194
Blast Score: 409

Bcl-2_like; Apoptosis regulator proteins of the Bcl-2 family, named after B-cell lymphoma 2. This alignment model spans what have been described as Bcl-2 homology regions BH1, BH2, BH3, and BH4. Many members of this family have an additional C-terminal...

cl02540
Location:1 – 27
Blast Score: 121

BH4; Bcl-2 homology region 4

RefSeqs of Annotated Genomes: Build 37.1

The following sections contain reference sequences that belong to a specific genome build. Explain

Genome Reference Consortium Human Build 37 (GRCh37), Primary_Assembly

Genomic

NC_000020.10

Range

30252260..30310655, complement

Download

GenBank FASTA Sequence Viewer (Graphics)
NT_011362.10

Range

448352..506747, complement

Download

GenBank FASTA Sequence Viewer (Graphics)

Alternate assembly (Celera)

Genomic

AC_000063.1

Range

27008610..27067006, complement

Download

GenBank FASTA Sequence Viewer (Graphics)
NW_927339.1

Range

511719..570115, complement

Download

GenBank FASTA Sequence Viewer (Graphics)

Alternate assembly (HuRef)

Genomic

AC_000152.1

Range

27040965..27099720

Download

GenBank FASTA Sequence Viewer (Graphics)
NW_001838664.2

Range

4580269..4639024

Download

GenBank FASTA Sequence Viewer (Graphics)

[Top][Help]Related Sequences

Nucleotide		Protein
genomic	AL117381.32	CAI23025.1
		CAI23026.1
		CAI23027.1
genomic	AL160175.5	CAC10003.1
		CAI12811.1
		CAI12812.1
		CAI12813.1
		CAI12814.1
		CAI12815.1
genomic	CH471077.2	EAW76424.1
		EAW76425.1
		EAW76426.1
		EAW76427.1
		EAW76428.1
		EAW76429.1
genomic	U72398.1	AAB17354.1
mRNA	AK290968.1	BAF83657.1
mRNA	AY263335.1	AAP22027.1
mRNA	AY263336.1	AAP22028.1
mRNA	BC019307.1	AAH19307.1
mRNA	BT007208.1	AAP35872.1
mRNA	BX647525.1	None
mRNA	CR936637.1	CAI56777.1
mRNA	Z23115.1	CAA80661.1
mRNA	Z23116.1	CAA80662.1
other-genetic	DQ893461.2	ABM84387.1
other-genetic	DQ896311.2	ABM87310.1

Protein Accession	Links
Q07817.1	GenPept	UniProtKB/Swiss-Prot:Q07817
Q5QP56	GenPept	UniProtKB/TrEMBL:Q5QP56
Q5QP59	GenPept	UniProtKB/TrEMBL:Q5QP59
Q5TE63	GenPept	UniProtKB/TrEMBL:Q5TE63
Q5TE64	GenPept	UniProtKB/TrEMBL:Q5TE64
Q9H1R6	GenPept	UniProtKB/TrEMBL:Q9H1R6